Mayer Davidson to Cost-Benefit Analysis
This is a "connection" page, showing publications Mayer Davidson has written about Cost-Benefit Analysis.
Connection Strength
0.579
-
Davidson MB. The "Cost-Effective" beneficial effect of pioglitazone on cardiovascular disease. Diabetes Res Clin Pract. 2020 07; 165:108223.
Score: 0.177
-
Zgibor JC, Kuo S, Emerson S, Gittinger P, Solano FX, Tilves D, Maloney M, Davidson MB. Rationale, design, and implementation of a cluster randomized trial using certified diabetes educators to intensify treatment for glycemia, blood pressure and lipid control: REMEDIES 4D. Contemp Clin Trials. 2014 Sep; 39(1):124-31.
Score: 0.118
-
Kahn R, Davidson MB. The reality of type 2 diabetes prevention. Diabetes Care. 2014 Apr; 37(4):943-9.
Score: 0.116
-
Davidson MB, Echeverry D. Collaborative care for depression and chronic illnesses. N Engl J Med. 2011 03 31; 364(13):1278; author reply 1278-9.
Score: 0.094
-
Davidson MB. Early insulin therapy for type 2 diabetic patients: more cost than benefit. Diabetes Care. 2005 Jan; 28(1):222-4.
Score: 0.061
-
Brandle M, Davidson MB, Schriger DL, Lorber B, Herman WH. Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes. Diabetes Care. 2003 Jun; 26(6):1796-801.
Score: 0.014